Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ibcasertib by Shenzhen Chipscreen Biosciences for Pancreatic Cancer: Likelihood of Approval
Ibcasertib is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
Ibcasertib by Shenzhen Chipscreen Biosciences for Colon Cancer: Likelihood of Approval
Ibcasertib is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase II for Colon Cancer. According to GlobalData,...
Ibcasertib by Shenzhen Chipscreen Biosciences for Non-Hodgkin Lymphoma: Likelihood of Approval
Ibcasertib is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData,...